Bee/Vespula Venom-Specific IgE Ratio Greater Than 5:1 Indicates Culprit Insect in Double-Sensitized Patients

Area of Science:

• Allergen immunotherapy
• Clinical immunology
• Diagnostic allergy testing

Background:

• Many patients allergic to insect venom are sensitized to both honeybee venom (BV) and Vespula venom (VV).
• Distinguishing true double allergy from cross-reactivity is crucial for effective treatment.
• Genuine double venom allergy is relatively uncommon.

Purpose of the Study:

• To determine if comparing specific IgE levels can identify the primary venom allergen in double-sensitized patients.
• To assess if component-resolved diagnostics are necessary for double immunotherapy decisions.

Main Methods:

• A retrospective analysis of 1,069 patients with a comprehensive allergological workup.
• Quantitative specific IgE testing for BV, VV, rApi m 1, and rVes v 5.
• Analysis of the BV/VV-specific IgE ratio in double-sensitized patients.

Main Results:

• A 5:1 or greater dominance in specific IgE levels to either BV or VV was observed in 52.1% of double-sensitized patients.
• In 97.1% of these cases, the dominant IgE level correctly predicted monoallergy to that specific venom.
• Component-resolved diagnostics were not always necessary when a clear IgE dominance was present.

Conclusions:

• A specific IgE ratio of 5:1 effectively identifies the culprit venom in double-sensitized patients.
• Component-resolved diagnostics can be reserved for cases with less than a 5:1 IgE ratio.
• Sensitization to specific components like rApi m 1 and rVes v 5 alone does not warrant double venom immunotherapy.